Warfarin Interactions With Substances Listed in Drug Information Compendia and in the FDA-Approved Label for Warfarin Sodium

被引:37
作者
Anthony, M. [1 ]
Romero, K. [1 ]
Malone, D. C. [2 ]
Hines, L. E. [3 ]
Higgins, L. [4 ]
Woosley, R. L. [1 ]
机构
[1] Crit Path Inst, Tucson, AZ USA
[2] Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA
[3] Univ Arizona, Coll Pharm, Ctr Hlth Outcomes & PharmacoEcon Res, Tucson, AZ 85721 USA
[4] Univ Arizona, Coll Med, Valley Fever Ctr Excellence, Tucson, AZ USA
基金
美国医疗保健研究与质量局;
关键词
DOSE REQUIREMENTS; ORAL ANTICOAGULATION; PRIMARY-CARE; THERAPY; HYPOPROTHROMBINEMIA; PROPYLTHIOURACIL; MEDICATION; POLYMORPHISMS; EVENTS; VKORC1;
D O I
10.1038/clpt.2009.95
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Interactions of warfarin with other drugs or substances can pose a serious problem. We assessed three drug information compendia-Clinical Pharmacology, ePocrates, and Micromedex-and the warfarin sodium (Coumadin) product label (August 2007) approved by the US Food and Drug Administration for listings of interactions between warfarin and drugs, biologics, foods, and dietary supplements. The drug information compendia and warfarin label differed greatly as to the total number of substances that interact with warfarin. Of a total of 648 entries from the four sources, only 50 were common to all the sources. The types of substances listed as interacting with warfarin were entire classes of drugs, individual drugs, and combinations; biologics; dietary supplements; foods; alcohol; and tobacco. These sources were then examined for classification by severity of interaction and the underlying evidence base. This study provides evidence that there is little concordance among commonly used drug compendia and product labels with respect to interactions involving warfarin.
引用
收藏
页码:425 / 429
页数:5
相关论文
共 32 条
[1]  
Abarca Jacob, 2004, J Am Pharm Assoc (2003), V44, P136, DOI 10.1331/154434504773062582
[2]   LOVASTATIN - WARFARIN INTERACTION [J].
AHMAD, S .
ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (11) :2407-2407
[3]   Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation [J].
Anderson, Jeffrey L. ;
Horne, Benjamin D. ;
Stevens, Scott M. ;
Grove, Amanda S. ;
Barton, Stephanie ;
Nicholas, Zachery P. ;
Kahn, Samera F. S. ;
May, Heidi T. ;
Samuelson, Kent M. ;
Muhlestein, Joseph B. ;
Carlquist, John F. .
CIRCULATION, 2007, 116 (22) :2563-2570
[4]  
[Anonymous], 2001, CROSS QUAL CHASM NEW
[5]   Consensus guidelines for coordinated outpatient oral anticoagulation therapy management [J].
Ansell, JE ;
Buttaro, ML ;
Thomas, IV ;
Knowlton, CH ;
Becker, DM ;
Bussey, HI ;
Corey, R ;
Gums, JG ;
Hughes, R ;
Jacobson, A ;
Kirchain, W ;
Kuhn, K ;
Loken, S ;
McCain, J ;
Haley, JA ;
Oertel, LB ;
Thrasher, K ;
Triplett, DA ;
Whitcomb, H ;
Wittkowsky, AK ;
Zarus, SA .
ANNALS OF PHARMACOTHERAPY, 1997, 31 (05) :604-615
[6]   Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements [J].
Aquilante, CL ;
Langaee, TY ;
Lopez, LM ;
Yarandi, HN ;
Tromberg, JS ;
Mohuczy, D ;
Gaston, KL ;
Waddell, CD ;
Chirico, MJ ;
Johnson, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) :291-302
[7]  
*ASS CHAIN DRUG ST, 2006, 2005 COMM PHARM PRES
[8]   The costs of adverse drug events in hospitalized patients [J].
Bates, DW ;
Spell, N ;
Cullen, DJ ;
Burdick, E ;
Laird, N ;
Petersen, LA ;
Small, SD ;
Sweitzer, BJ ;
Leape, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04) :307-311
[9]   The impact of computerized physician order entry on medication error prevention [J].
Bates, DW ;
Teich, JM ;
Lee, J ;
Seger, D ;
Kuperman, GJ ;
Ma'Luf, N ;
Boyle, D ;
Leape, L .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 1999, 6 (04) :313-321
[10]  
*BRIST MYERS SQUIB, 2007, COUM PRESCR INF